Nuveen
PVLA

Nuveen’s Palvella Therapeutics PVLA Stock Holding History

Nuveen’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Buy
25,231
+4,397
+21% +$534K ﹤0.01% 2237
2026
Q1 		$2.6M Buy
20,834
+1,258
+6% +$131K ﹤0.01% 2170
2025
Q4 		$2.05M Buy
19,576
+6,871
+54% +$586K ﹤0.01% 2282
2025
Q3 		$796K Buy
12,705
+3,800
+43% +$169K ﹤0.01% 2726
2025
Q2 		$201K Buy
+8,905
New +$209K ﹤0.01% 3159
2021
Q2 		– Sell
-2,084
Closed -$428K – 3557
2021
Q1 		$428K Buy
2,084
+15
+0.7% +$3.28K ﹤0.01% 3122
2020
Q4 		$414K Buy
2,069
+22
+1% +$4.58K ﹤0.01% 3082
2020
Q3 		$339K Hold
2,047
– – ﹤0.01% 3055
2020
Q2 		$508K Sell
2,047
-114
-5% -$26.7K ﹤0.01% 2889
2020
Q1 		$394K Sell
2,161
-2,855
-57% -$719K ﹤0.01% 2854
2019
Q4 		$1.45M Buy
5,016
+552
+12% +$153K ﹤0.01% 2549
2019
Q3 		$1.22M Sell
4,464
-3,544
-44% -$1.37M ﹤0.01% 2614
2019
Q2 		$3.01M Buy
+8,008
New +$2.39M ﹤0.01% 2246

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Nuveen's PVLA Position: Q2 2026 in Review

Nuveen increased its Palvella Therapeutics (PVLA) stake by 21% in Q2 2026, buying an estimated $534K and bringing the position to 25,231 shares worth $3.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

Nuveen first reported a position in PVLA in Q2 2019 and has held it in 13 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Nuveen held 25,231 shares of Palvella Therapeutics worth $3.86M as of Q2 2026.
  • Nuveen bought 4,397 Palvella Therapeutics shares in Q2 2026, an estimated $534K.
  • Palvella Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2237 holding.
  • Nuveen first reported a position in Palvella Therapeutics in Q2 2019 and has held it in 13 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.